Inhibitory effects of topical cyclosporine A 0.05 % on immune-mediated corneal neovascularization in rabbits

[1]  P. Prabhasawat,et al.  A Randomized Double-Masked Study of 0.05% Cyclosporine Ophthalmic Emulsion in the Treatment of Meibomian Gland Dysfunction , 2012, Cornea.

[2]  S. Tuft,et al.  Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial , 2012, British Journal of Ophthalmology.

[3]  B. Gurler,et al.  Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis , 2012, BMC Ophthalmology.

[4]  Yong Liu,et al.  Topical application of FTY720 and cyclosporin A prolong corneal graft survival in mice , 2012, Molecular vision.

[5]  R. Dana,et al.  Corneal penetration of topical and subconjunctival bevacizumab. , 2011, Investigative ophthalmology & visual science.

[6]  N. Lagali,et al.  Cellular level characterization of capillary regression in inflammatory angiogenesis using an in vivo corneal model , 2011, Angiogenesis.

[7]  D. Gupta,et al.  Treatments for Corneal Neovascularization: A Review. , 2011, Cornea.

[8]  K. Tsubota,et al.  Prospective, randomized study of the efficacy of systemic cyclosporine in high-risk corneal transplantation. , 2006, American journal of ophthalmology.

[9]  R. Katz,et al.  Efficacy of topical cyclosporine for the treatment of ocular rosacea , 2009, Advances in therapy.

[10]  Claus Cursiefen,et al.  Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin®) eye drops against corneal neovascularization , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.

[11]  R. Dana,et al.  Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. , 2009, Archives of ophthalmology.

[12]  E. Lamoureux,et al.  Topical Cyclosporin A in the treatment of acute graft rejection: a randomized controlled trial , 2008, Clinical & experimental ophthalmology.

[13]  F. Kruse,et al.  Bevacizumab (Avastin) eye drops inhibit corneal neovascularization , 2008, Graefe's Archive for Clinical and Experimental Ophthalmology.

[14]  D. Coster,et al.  The Immunobiology of Corneal Transplantation , 2007, Transplantation.

[15]  M. Erdurmuş,et al.  Inhibitory Effects of Topical Thymoquinone on Corneal Neovascularization , 2007, Cornea.

[16]  M. Erdurmuş,et al.  Subconjunctival bevacizumab for corneal neovascularization , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[17]  F. Bock,et al.  [Inhibition of angiogenesis in the anterior chamber of the eye]. , 2007, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

[18]  D. Böhringer,et al.  Clear graft survival and immune reactions following emergency keratoplasty , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[19]  R. Rao,et al.  Efficacy of Topical Cyclosporine 0.05% in the Treatment of Dry Eye Associated With Graft Versus Host Disease , 2006, Cornea.

[20]  M. Smolek,et al.  Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry‐eye patients having laser in situ keratomileusis , 2006, Journal of cataract and refractive surgery.

[21]  N. Mitsiades,et al.  VEGF-dependent conjunctivalization of the corneal surface. , 2003, Investigative ophthalmology & visual science.

[22]  B. Seitz,et al.  Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study , 2002, Graefe's Archive for Clinical and Experimental Ophthalmology.

[23]  Shin-Seok Lee,et al.  Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts. , 2002, Arthritis and rheumatism.

[24]  齋田 典夫.  Trehalose 6,6'-dimycolate (cord factor) of Mycobacterium tuberculosis induces corneal angiogenesis in rats , 2002 .

[25]  J. Redondo,et al.  Selective Inhibition of Vascular Endothelial Growth Factor–Mediated Angiogenesis by Cyclosporin a , 2001, The Journal of experimental medicine.

[26]  D. Azar,et al.  Corneal neovascularization. , 2001, Current opinion in ophthalmology.

[27]  C. Humpel,et al.  Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. , 2000, Investigative ophthalmology & visual science.

[28]  K. Baratz,et al.  Indiscriminate use of corticosteroid-containing eyedrops. , 1999, Mayo Clinic proceedings.

[29]  A. Adamis,et al.  Ocular neovascularization: an epidemiologic review. , 1998, Survey of ophthalmology.

[30]  M. Hingorani,et al.  A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. , 1998, Ophthalmology.

[31]  M. Nardi,et al.  Corneal neovascularization induced by xenografts or chemical cautery. Inhibition by cyclosporin A. , 1997, Investigative ophthalmology & visual science.

[32]  R. D. Stulting,et al.  Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. , 1994, Ophthalmology.

[33]  R. Hendricks,et al.  Suppression of corneal neovascularization with cyclosporine. , 1992, Archives of ophthalmology.

[34]  R. D. Stulting,et al.  Corneal neovascularization. Pathogenesis and inhibition. , 1987, Cornea.

[35]  I. Jones,et al.  Inhibition of Vascularization of the Rabbit Cornea by Local Application of Cortisone.∗ , 1950, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.